SYNOPSIS
Background Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2. Presently, data on the effectiveness and optimal dosage of favipiravir for treating COVID-19 is limited.
Methods We conducted a retrospective observational study of hospitalized adult patients with COVID-19 at five tertiary care hospitals in Thailand. We reviewed patient charts to obtain all necessary data.
Results Among 247 COVID-19 patients, 63 (23.0%) received ≥1 dose of favipiravir. Of these, 27.0% required an O2-nasal cannula, 9.5% required non-invasive ventilation and/or high-flow O2-therapy, and 6.4% required invasive mechanical ventilation and/or ECMO. The median baseline NEWS2 score was 5(0–16). The Day-7 clinical improvement rate [95%CI] was 66.7%[53.7–78.0%] in all patients, 92.5%[75.7%–99.1%] in patients who did not require O2-supplementation, and 47.2%[0.4%–64.5%] in patients who required O2-supplementation. No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%.
Multivariate analysis revealed three poor prognostic factors for Day-7 clinical improvement [odds ratio (95%CI); p-value]: older age [0.94 (0.89–0.99); p=0.04], higher baseline NEWS2 score [0.64 (0.47–0.88); p=0.006], and lower favipiravir loading dose (≤45 mg/kg/day) [0.04 (0.005–0.4); p=0.006].
Conclusions Our study reports the promising effectiveness of favipiravir for treating COVID-19 patients. In addition to older age and a high baseline NEWS2 score, a low loading dose of favipiravir (≤45 mg/kg/day) was also identified as a poor prognostic factor for early clinical improvement. Further studies to explore the optimal dose and the optimal timing of drug initiation for favipiravir should be performed.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
This research project was supported by Siriraj Research Fund, Grant number (IO) R016333038, Faculty of Medicine Siriraj Hospital, Mahidol University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved with a waiver of informed consent by the institutional review boards of all involved hospitals.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All datasets are available upon request.
